Experience With Afatinib in Patients With Non-Small Cell Lung Cancer Progressing After Clinical Benefit From Gefitinib and Erlotinib

BACKGROUND. Afatinib, an irreversible ErbB family blocker, demonstrated superiority to chemotherapy as first-line treatment in patients with EGFR-mutated non-small cell lung cancer (NSCLC). Afatinib is also active in patients progressing on EGFR tyrosine kinase inhibitors (EGFR-TKIs). We report the...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Schuler, Martin, Fischer, Jürgen R., Grohé, Christian, Gütz, Sylvia, Thomas, Michael, Kimmich, Martin, Schneider, Claus-Peter, Laack, Eckart, Märten, Angela
Médium: Artigo
Jazyk:Inglês
Vydáno: AlphaMed Press 2014
Témata:
Lung Cancer
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4200993/
https://ncbi.nlm.nih.gov/pubmed/25232040
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2014-0103
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky